Studies have exhibited promising outcomes concerning the DC-tumor fusion vaccine therapy of diverse cancer types through the blockade of CTLA-4 [22], which signifies that targeting immune inhibitory molecules is able to impede T cell-mediated antitumor immunity. The gene discussed is CTLA4; the disease is neoplasm.